Aspen Investor Presentation — June 2022

Document content

Annual Results Presentation

For the year ended 30 June 2022DISCLAIMER

We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future r esults and estimates of amounts not

yet determinable. These are forward looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “prospects”, “believe”,

“anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate”, “could”, “may”, “endeavour ” and “project” and similar expressions are intended to identify such

forward looking statements but are not the exclusive means of identifying such statements. By their very nature, forward -looking statements involve inherent risks

and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections and other forward -looking statements will not be achieved. If

one or more of these risks materialise, or should underlying assumptions prove incorrect, actual results may be very different from those anticipated. The factors tha t

could cause our actual results to differ materially from the plans, objectives, expectations, estimates and intentions expres sedinsuch forward -looking statements are

discussed in each year’s annual report. ​​

Forward looking statements apply only as of the date on which they are made, and we do not undertake other than in terms of t he Listings Requirements of the JSE

Limited, any obligation to update or revise any of them, whether as a result of new information, future events or otherwise. Any profit forecasts published in this

report are unaudited and have not been reviewed or reported on by Aspen's external auditors. ​

2CAUTIONARY REGARDING FORWARD -LOOKING STATEMENTSDISCLOSURE NOTE

​RESTATEMENT OF THE GROUP SEGMENTAL ANALYSIS

The Group has revised its reportable segments to reflect the newly updated operating model which aligns to the way in which t h e business is managed

and reported on by the Chief Operating Decision Maker (“CODM”).

The business segments which make up the Pharmaceutical segment have been revised as follows:​

»Commercial responsibility for Israel has been moved to Africa Middle East from Europe CIS and consequently the prior year num b ers

•(June 2021: R122m) h ave been restated to reflect this segmental change.

There has been no material negative impact of COVID -1 9 on the Group's financial performance and no asset impairments have arisen as a consequence of

COVID -19 (“COVID”).

3Financial ReviewNormalised

per share (cents)+26% CERⱡ

Margin %Normalised EBITDA